Nutricia welcomes the publication in the Journal of Pediatric Gastroenterology and Nutrition of a safety and tolerance study of a novel anti-regurgitation baby formula
Nutricia is pleased to announce publication in the Journal of Pediatric Gastroenterology and Nutrition (JPGN) of the results of a study comparing a baby formula indicated for the dietary management of regurgitation with an anti-regurgitation (AR) baby formula containing pre- and postbiotics1.
The study, entitled “Safety and Tolerance of a Novel Anti-Regurgitation Formula: A double-blind, randomized, controlled trial”, showed that the AR baby formula containing pre- and post-biotics was safe and well tolerated by infants with regurgitation. A post-hoc analysis of the trial data also determined that the AR baby formula containing pre- and postbiotics led to a greater improvement among those infants with the most severe gastrointestinal symptoms – such as stooling, spitting-up/vomiting, crying, fussiness and flatulence. Nutricia is supporting such research to understand and highlight how certain gastrointestinal conditions that affect infants and babies can be managed through nutritional interventions – such as AR formulas containing pre- and postbiotics.
During the design and setup of the study, only those parents who had already decided to fully formula feed were informed about the study. Parents were asked to complete the Infant Gastrointestinal Symptom Questionnaire (IGSQ) – a method whereby parents record their baby’s incidents of stooling, spitting-up/vomiting, crying, fussiness and flatulence. Completed questionnaires were converted into IGSQ scores to compare the established AR baby formula with the AR baby formula containing pre- and postbiotics.